ReviewMolecules (Basel, Switzerland)2020
The Rise of Synaptic Density PET Imaging.
Review in Molecules (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- A systematic review and meta-analysis of neuroimaging studies examining synaptic density in individuals with psychotic spectrum disorders.BMC psychiatry · 2024Pooled it
- Quantitative monitoring of ketamine's impact on synaptic density usingMolecular psychiatry · 2026Article
- SV2A PET reveals synaptic density loss in experimental autoimmune encephalomyelitis and in a pilot multiple sclerosis study.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- HIV-1 Tat expression drives progressive synaptic decline: evidence from longitudinal [NeuroImmune pharmacology and therapeutics · 2026Article
- Increased Expression of Synaptic Vesicle Glycoprotein 2A (SV2A) in the Brain of Chronic Diabetic Rats.Synapse (New York, N.Y.) · 2025Article
- Multi-target approach to Alzheimer's disease prevention and treatment: antioxidant, anti-inflammatory, and amyloid- modulating mechanisms.Neurogenetics · 2025Review
- Neuroplasticity in Diffuse Low-grade Gliomas: Backward Modelling of Brain-tumor Interactions Prior to Diagnosis is Needed to Better Predict Recovery after Treatment.Current neurology and neuroscience reports · 2025Review
- Exploring the Interactions between two Ligands, UCB-J and UCB-F, and Synaptic Vesicle Glycoprotein 2 Isoforms.ACS chemical neuroscience · 2024Article
- Structural basis for antiepileptic drugs and botulinum neurotoxin recognition of SV2A.Nature communications · 2024Article
- Synaptic injury in the inner plexiform layer of the retina is associated with progression in multiple sclerosis.Cell reports. Medicine · 2024Article
- Estimating the synaptic density deficit in Alzheimer's disease using multi-contrast CEST imaging.PloS one · 2024Article
- Brain Trauma Imaging.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Oxidation-Cyclisation of Biphenyl Thioethers to Dibenzothiophenium Salts for UltrarapidInternational journal of molecular sciences · 2022Article
- Organocatalytic Asymmetric Synthesis of SynVesT-1, a Synaptic Density Positron Emission Tomography Imaging Agent.The Journal of organic chemistry · 2022Article
- Spatial decrease of synaptic density in amnestic mild cognitive impairment follows the tau build-up pattern.Molecular psychiatry · 2022Article
- A metabolically stable PET tracer for imaging synaptic vesicle protein 2A: synthesis and preclinical characterization of [European journal of nuclear medicine and molecular imaging · 2022Article
- Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer.International journal of molecular sciences · 2021Article
- Neuroimaging brain growth charts: A road to mental health.Psychoradiology · 2021Article
- The pharmacokinetics of [EJNMMI research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many neurological disorders are related to synaptic loss or pathologies. Before the boom of positrons emission tomography (PET) imaging of synapses, synaptic quantification could only be achieved in vitro on brain samples after autopsy or surgical resections. Until the mid-2010s, electron microscopy and immunohistochemical labelling of synaptic proteins were the gold-standard methods for such analyses. Over the last decade, several PET radiotracers for the synaptic vesicle 2A protein have been developed to achieve in vivo synapses visualization and quantification. Different strategies were used, namely radiolabelling with either
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.